Loading…
Employees: 863
Size SBC Medical (SBC) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $518M, the 2669th largest of 3,117 United States companies the cockpit tracks. Shares closed at $5.04 on 6 Nov 2026.
Performance Over six months the shares gained 58.5%, against -22.6% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 8 in its peer set.
Growth Revenue fell 6.9% over the last twelve months (peer median -6.1%); the operating margin is 37.3% (peer median -115.5%).
Valuation It trades at 10.3× forward earnings.
Price implies For today's price to make sense, revenue must grow about -16% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is -9 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 25.1 points above its cost of capital (7.3% WACC).
Short interest Short interest is 0.7% of the free float (15 Oct 2026).
Next results Next results expected around 13 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $175M | $174M | $205M | $194M | $0 |
| Revenue growth | — | -15% | +6% | — | — |
| Gross profit | $124M | $126M | $154M | $126M | $0 |
| EBITDA | $68.6M | $70.2M | $89.2M | $83.3M | -$543,700 |
| Net income | $49.0M | $51.0M | $46.6M | $39.4M | $552,813 |
| Free cash flow | $75.0M | $36.6M | $51.9M | $41.2M | -$462,820 |
| Capital expenditure | $2.54M | $2.79M | $3.41M | $11.2M | $0 |
| Total debt | $48.2M | $51.6M | $12.2M | $22.9M | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SBC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.6% | -2.6% | 4th lowest of 8 |
| 6-month return | +58.5% | -22.6% | 2nd highest of 8 |
| Distance from 52-week high | -13.0% | -40.4% | 2nd highest of 8 |
| Revenue growth (TTM) | -6.9% | -6.1% | 3rd highest of 5 |
| Operating margin | 37.3% | -115.5% | highest of 6 |
| Forward P/E | 10.3× | n/a | — |
| Growth the price implies (Req g, 7 yrs) | -16.1% | n/a | — |
| Growth delivered (Del g) | -6.9% | n/a | — |
| Hurdle (Req g minus delivered) | -9.2 pp | n/a | — |
| ROIC minus cost of capital | +25.1 pp | -21.3 pp | highest of 4 |
| EV / EBITDA | 5.8× | n/a | — |
| Net debt / EBITDA | -2.0× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SBC Medical SBC | United States | $518M | +58% | -7% | 37% | 10.3× | -16.1% | -6.9% |
| Evolent Health EVH | United States | $518M | +10% | -4% | -1% | 12.1× | 22.6% | +15.2% |
| Oculis OCS | United States | $462M | -77% | n/a | n/a | n/a | n/a | n/a |
| Adlai Nortye Ltd. Sponsored ADR ANL | United States | $619M | -23% | n/a | -134% | n/a | n/a | n/a |
| Evotec EVT.DE | Germany | $630M | -33% | -8% | -19% | n/a | n/a | n/a |
| Tectonic Therapeutic TECX | United States | $403M | -29% | n/a | n/a | n/a | n/a | n/a |
| OmniAb OABI | United States | $734M | +29% | +91% | -116% | n/a | 59.6% | -31.9% |
| Silence Therapeutics PLC Sponsored ADR SLN | United States | $1.23B | +184% | -97% | -10,478% | n/a | n/a | n/a |